CoreCap Advisors’s Fate Therapeutics FATE Stock Holding History

CoreCap Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-255	Closed	-$201	–	2920
2025 Q1	$201	Buy	+255	New	+$313	﹤0.01%	2976
2024 Q4	–	Sell	-133	Closed	-$466	–	2896
2024 Q3	$466	Buy	+133	New	+$518	﹤0.01%	2375
2022 Q1	–	Sell	-155	Closed	-$9K	–	1030
2021 Q4	$9K	Buy	+155	New	+$8.79K	﹤0.01%	1580

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CoreCap Advisors's FATE Position: Q2 2025 in Review

CoreCap Advisors sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 255 shares — an estimated $201 sold.

CoreCap Advisors first reported a position in FATE in Q4 2021 and held it in 3 quarters. The position peaked at $9K in Q4 2021. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

CoreCap Advisors reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 255 Fate Therapeutics shares in Q2 2025, an estimated $201.
CoreCap Advisors first reported a position in Fate Therapeutics in Q4 2021 and held it in 3 quarters.
CoreCap Advisors's Fate Therapeutics position peaked at $9K in Q4 2021.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.